Stocks › UTHR
UNITED THERAPEUTICS Corp
UTHR·Nasdaq·
United States·USD
United States·USD$541.62
+5.22 (+0.97%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
UTHR
UNITED THERAPEUTICS Corp · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
UTHRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of UTHR by members of U.S. Congress · 52 on record · 4 in the last 12 months
Whale Activity
Position changes in UTHR reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Ridgewood Investments LLC | 3,209 | $1.7M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by UTHR insiders, by quarter · Form 4
Recent Insider Transactions
10,369 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −931 | $539.50 | $502K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −920 | $545.69 | $502K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −918 | $542.56 | $498K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −905 | $537.43 | $486K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −783 | $543.54 | $426K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −655 | $538.62 | $353K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −501 | $536.26 | $269K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −360 | $546.63 | $197K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −1,260 | $544.59 | $686K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −1,239 | $541.66 | $671K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −1,028 | $540.50 | $556K | Oct 5, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −80 | $572.44 | $46K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −80 | $566.58 | $45K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −80 | $563.88 | $45K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −80 | $555.60 | $44K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −80 | $554.30 | $44K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −757 | $549.59 | $416K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −725 | $551.82 | $400K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −700 | $542.06 | $379K | Oct 2, 2026 | Form 4 ↗ |
| ROTHBLATT MARTINE AChairperson & CEO · Director | Sale | −432 | $550.99 | $238K | Oct 2, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding UTHR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 1.5M | $787.1M | 0.63% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $730.2M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 973.5K | $527.5M | 0.28% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 719.4K | $372.4M | 0.98% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 486.6K | $263.6M | 0.27% | Jun 30, 2026 |
| State Street SPDR S&P MidCap 400SM ETF Trust SPDR S&P MIDCAP 400 ETF TRUST | 326.6K | $176.9M | 0.63% | Jun 30, 2026 |
| VANGUARD U.S. GROWTH FUND VANGUARD WORLD FUND | 304.1K | $169.3M | 0.36% | May 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 308.3K | $167.1M | 0.25% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 290.8K | $157.6M | 1.73% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 280.8K | $152.1M | 0.32% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list UTHR's shares (CUSIP 91307C102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- ROTHBLATT MARTINE ASCHEDULE 13G/A · passive (13G) · 2.3M shares5.3%
Aug 14, 2026 · ↗ - Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming united therapeutics as client
- TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2026 Q2 · HCR$80K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2026 Q1 · HCR$80K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2025 Q4 · POS$60K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2025 Q3$20K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2025 Q3 · HCR—
Filing ↗
Government Contracts
Federal awards to united therapeutics · USAspending
$200KAwarded · 11 contracts on record
- Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$30K
Aug 27, 2025 · ↗ - Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$0
Apr 8, 2026 · ↗ - Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$16K
Jul 21, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jul 16, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jul 9, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jun 25, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jun 11, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG$17K
Jun 5, 2026 · ↗
U.S. Patents
Recent USPTO applications naming UNITED THERAPEUTICS Corp
No USPTO patent applications found for UNITED THERAPEUTICS Corp.
Annual Financials
From UTHR's 10-K filings · XBRL
No annual XBRL figures on record for UTHR. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitSep 23, 2009
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 23, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About UNITED THERAPEUTICS Corp
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSILVER SPRING, MD
IncorporatedDE
SEC CIK0001082554 ↗